CQUniversity
Browse

File(s) not publicly available

Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer

journal contribution
posted on 2018-08-07, 00:00 authored by CA Azad, S Jackson, C Cullinane, A Natoli, Paul NeilsenPaul Neilsen, DF Callen, SM Maira, W Hackl, GA McArthur, B Solomon
DNA-dependent protein kinase (DNA-PK) plays a pivotal role in the repair of DNA double-strand breaks (DSB) and is centrally involved in regulating cellular radiosensitivity. Here, we identify DNA-PK as a key therapeutic target for augmenting accelerated senescence in irradiated human cancer cells. We find that BEZ235, a novel inhibitor of DNA-PK and phosphoinositide 3-kinase (PI3K)/mTOR, abrogates radiation-induced DSB repair resulting in cellular radiosensitization and growth delay of irradiated tumor xenografts. Importantly, radiation enhancement by BEZ235 coincides with a prominent p53-dependent accelerated senescence phenotype characterized by positive β-galactosidase staining, G 2 -M cell-cycle arrest, enlarged and flattened cellular morphology, and increased p21 expression and senescence-associated cytokine secretion. Because this senescence response to BEZ235 is accompanied by unrepaired DNA DSBs, we examined whether selective targeting of DNA-PK also induces accelerated senescence in irradiated cells. Significantly, we show that specific pharmacologic inhibition of DNA-PK, but not PI3K or mTORC1, delays DSB repair leading to accelerated senescence after radiation. We additionally show that PRKDC knockdown using siRNA promotes a striking accelerated senescence phenotype in irradiated cells comparable with that of BEZ235. Thus, in the context of radiation treatment, our data indicate that inhibition of DNA-PK is sufficient for the induction of accelerated senescence. These results validate DNA-PK as an important therapeutic target in irradiated cancer cells and establish accelerated senescence as a novel mechanism of radiosensitization induced by DNA-PK blockade. ©2011 AACR.

Funding

Other

History

Volume

9

Issue

12

Start Page

1696

End Page

1707

Number of Pages

13

eISSN

1557-3125

ISSN

1541-7786

Publisher

American Association for Cancer Research

Peer Reviewed

  • Yes

Open Access

  • No

External Author Affiliations

Peter MacCallum Cancer Centre; , University of Melbourne; e, University of Adelaide and Hanson Institute; Novartis Pharma AG

Era Eligible

  • Yes

Journal

Molecular Cancer Research

Usage metrics

    CQUniversity

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC